PCSK9 and familial hypercholesterolemia: Lowering LDL-C levels is currently the main treatment goal in familial hypercholesterolemia and shows an approximately linear relationship with the incidence of ASCVD.2,30 Lowering LDL-C with PCSK9 inhibitors also significantly reduces ASCVD risk.31,32 Therefore, effective lowering of LDL-C by inclisiran, over time, can also be expected to decrease the risk of ASCVD, which is currently being evaluated in adults in two ongoing studies (NCT03705234 and NCT05030428).